Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

HUTCHMED (China) Limited - American Depositary Shares (HCM) 
Company Research Source: GlobeNewswire
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform (“PI3Kd”) inhibitor, in patients with relapsed or refractory lymphoma.  The first patient was dosed on August 26, 2019 in the U.S. The international clinical study, with sites in the U.S. and Europe, is a multi-center, open-label, two-stage study, including dose escalation and expansion, investigating the effects of HMPL-689 administered orally to patients with relapsed or refractory lymphoma.  The primary outcome measures are safety and tolerability.  Secondary outcomes include pharmacokinetic (“PK”) measurements and preliminary efficacy such as objective response rate (ORR).  The co-lead investigators of the study are Dr. Nilanjan Ghosh (Lymphoma Program Director, Levine Cancer Institute-Morehead, Charlotte, NC), and Dr. Jo Show less Read more
Impact Snapshot
Event Time:
HCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HCM alerts
Opt-in for
HCM alerts

from News Quantified
Opt-in for
HCM alerts

from News Quantified